At a glance
A combined research record involving CJC-1295 DAC and ipamorelin in separate vials.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
This record brings together CJC-1295 DAC and ipamorelin in separate vials. The scientific rationale draws on the component pathways, but a plausible combination is not proof of an additive or synergistic clinical effect. Identify the exact components, formulation and relative amounts before comparing it with a published study.[1][2][3]
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.[6][1][2]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of CJC-1295 DAC + Ipamorelin.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg + 5 mg · 3 source tables
CJC-1295 DAC (5 mg Vial) — Subcutaneous, Once Weekly
| Phase | Weekly Dose (mcg / mg) | Units (mL) per Injection | Frequency |
|---|---|---|---|
| Standard | 1000 mcg (1.0 mg) | 40 units (0.40 mL) | Once weekly |
| Aggressive | 2000 mcg (2.0 mg) | 80 units (0.80 mL) | Once weekly |
Reconstitution: 2.0 mL bacteriostatic water → 2.5 mg/mL (2500 mcg/mL) → 25 mcg per unit Note: At 2.5 mg/mL, each 5 mg vial provides 2.5 standard doses (1 mg each) or 1.25 aggressive doses (2 mg each).
Ipamorelin (5 mg Vial) — Subcutaneous, Once Daily
| Phase | Daily Dose (mcg / mg) | Units (mL) per Injection | Frequency |
|---|---|---|---|
| Weeks 1–2 (Initiation) | 100 mcg (0.1 mg) | 6 units (0.06 mL) | Once daily |
| Weeks 3–4 (Titration) | 150 mcg (0.15 mg) | 9 units (0.09 mL) | Once daily |
| Weeks 5+ (Maintenance) | 200 mcg (0.2 mg) | 12 units (0.12 mL) | Once daily |
| Aggressive (Optional) | 300 mcg (0.3 mg) | 18 units (0.18 mL) | Once daily or split 2×/day |
Reconstitution: 3.0 mL bacteriostatic water → 1.67 mg/mL (1666.7 mcg/mL) → 16.67 mcg per unit For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Combined Stack Schedule — Standard Approach
| Week | CJC-1295 DAC (Weekly) | Ipamorelin (Daily) |
|---|---|---|
| Weeks 1–2 | 1000 mcg (40 units) once weekly | 100 mcg (6 units) once daily |
| Weeks 3–4 | 1000 mcg (40 units) once weekly | 150 mcg (9 units) once daily |
| Weeks 5–12 | 1000 mcg (40 units) once weekly | 200 mcg (12 units) once daily |
Timing: CJC-1295 DAC is typically administered on a fixed day each week. Ipamorelin is commonly administered before bed to coincide with natural nocturnal GH pulses[4]. Important: This guide is for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
Additional schedule context & duration
Concise summary of the stacked GH secretagogue regimen.
- Goal: Amplify endogenous GH/IGF-1 secretion through dual GHRH and ghrelin-receptor pathways[3].
- Schedule: CJC-1295 DAC once weekly + Ipamorelin once daily for 8–16 weeks.
- CJC-1295 DAC Dose: 1–2 mg weekly (standard: 1 mg).
- Ipamorelin Dose: 100–300 mcg daily with gradual titration.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze–thaw cycles.
Suggested approach for the stacked regimen.
- CJC-1295 DAC: 1 mg (40 units) subcutaneously once per week on a consistent day.
- Ipamorelin: Start at 100 mcg (6 units) daily; titrate to 200 mcg (12 units) by Week 5.
- Timing: Ipamorelin before bed aligns with natural nocturnal GH release[4].
- Cycle Length: 8–12 weeks standard; extend to 16 weeks if tolerated.
- Injection Sites: Rotate abdomen, thighs, and upper arms.
Preparation
CJC-1295 DAC Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or direct stream onto powder.
- Gently swirl/roll until fully dissolved (do not shake).
- Label with date and refrigerate at 2–8 °C (35.6–46.4 °F).
Ipamorelin Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label with date and refrigerate at 2–8 °C (35.6–46.4 °F).
Storage Instructions
Proper storage preserves peptide integrity and efficacy.
- Lyophilized (dry powder): Store at ≤−15 °C (5 °F); preferably ≤−50 °C (−58 °F) for long-term storage[5].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks[5].
- Allow vials to reach room temperature before opening to minimize condensation uptake.
- Avoid repeated freeze–thaw cycles of reconstituted solutions.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[8].
- Clean the vial stopper and skin with alcohol; allow to dry completely.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[8].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
- Limit each injection to ≤1 mL; split larger volumes into separate injections[8].
Materials & quantity planning
Source materials checklist · 5 mg + 5 mg
Plan based on an 8–16 week stacked protocol with standard dosing (CJC-1295 DAC 1 mg/week + Ipamorelin 200 mcg/day at maintenance).
-
CJC-1295 DAC Vials (5 mg each):
- 8 weeks (8 mg total) → 2 vials
- 12 weeks (12 mg total) → 3 vials
- 16 weeks (16 mg total) → 4 vials
-
Ipamorelin Vials (5 mg each):
- 8 weeks (56 days at ~200 mcg/day) → 3 vials
- 12 weeks (84 days) → 4 vials
- 16 weeks (112 days) → 5 vials
-
Insulin Syringes (U-100):
- Per week: 1 (CJC) + 7 (Ipamorelin) = 8 syringes
- 8 weeks: 64 syringes
- 12 weeks: 96 syringes
- 16 weeks: 128 syringes
- For Ipamorelin doses ≤10 units, 30- or 50-unit syringes improve accuracy.
-
Bacteriostatic Water (10 mL bottles):
- 8 weeks: CJC (2 × 2 mL = 4 mL) + Ipam (3 × 3 mL = 9 mL) = 13 mL → 2 × 10 mL bottles
- 12 weeks: CJC (3 × 2 mL = 6 mL) + Ipam (4 × 3 mL = 12 mL) = 18 mL → 2 × 10 mL bottles
- 16 weeks: CJC (4 × 2 mL = 8 mL) + Ipam (5 × 3 mL = 15 mL) = 23 mL → 3 × 10 mL bottles
-
Alcohol Swabs:
- Per week: ~16 swabs (2/day for Ipamorelin + 2 for CJC weekly)
- 8 weeks: 128 swabs → 2 × 100-count boxes
- 12 weeks: 192 swabs → 2 × 100-count boxes
- 16 weeks: 256 swabs → 3 × 100-count boxes
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
Journal of Clinical Endocrinology & Metabolism — Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 02
Research publication
European Journal of Endocrinology — Ipamorelin, the first selective growth hormone secretagogue (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 03
Research publication
Endocrine Reviews — Growth hormone secretagogues: mechanisms and clinical applications (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
Sleep Medicine Reviews — Sleep and the GH/IGF-1 axis: physiological and clinical implications (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Source document
Bachem — Handling and storage guidelines for peptides (lyophilized stability) (opens in a new tab)www.bachem.com
Back to overview ↑ - 06
Research publication
Translational Andrology and Urology (PMC) — GH secretagogues in body composition management for hypogonadal males (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Research publication
International Journal of Surgery (PubMed) — Ipamorelin for postoperative ileus: tolerability and safety in bowel resection patients (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 08
Public health resource
NCBI Bookshelf — Parenteral medication administration: subcutaneous injection technique (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Public health resource
CDC — Vaccine administration guidelines: subcutaneous route (no aspiration required) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 10
Source document
Growth Hormone & IGF Research (ScienceDirect) — Ipamorelin induces longitudinal bone growth in rats (opens in a new tab)www.sciencedirect.com
Back to overview ↑ - 11
Research publication
Physiological Reviews — The somatotropic axis: GH and IGF-1 regulation and actions (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 12
Research publication
Clinical Drug Investigation (PMC) — Subcutaneous drug delivery: pharmacokinetic considerations (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.